Topic: PCSK9

Novartis

4. Novartis

Novartis kept things busy in 2019 as it continued to focus on becoming a top medicines company. It spun off eye care medtech business Alcon, and at the same time bought legacy Shire’s Xiidra to boost its ophthalmic drug franchise and acquired The Medicines Company for cholesterol-lowering med inclisiran.
Novartis headquarters

6. Novartis/The Medicines Company

Novartis has agreed to buy The Medicines Company for $85 per share in a $9.7 billion cash transaction, a price that it might have overpaid. Though it’s buying the entire firm, the deal is really just about one drug: cardiovascular contender inclisiran.